Navigation Links
Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
Date:9/1/2009

NEW YORK, Sept. 1 /PRNewswire/ -- Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain. Now, a paper published in the current issue of Cell Metabolism (Vol. 10, Issue 3, Sept. 2, 2009) elaborates on a separate TGR5-regulated mechanism in the gut that drives secretion of the hormone glucagon-like peptide (GLP-1) and resulting insulin sensitization.

The paper reports on the mechanism of action of the selective TGR5 agonist INT-777, providing a clear rationale for its potential as a novel treatment in diabetes, obesity and associated metabolic disorders. INT-777 is a patent-pending modified human bile acid that is currently being advanced to an IND by Intercept Pharmaceuticals, Inc. This proprietary compound was discovered by the company's scientific founder and head of medicinal chemistry, Professor Roberto Pellicciari. The newly published results were generated through a longstanding exclusive Intercept research collaboration with Professor Pellicciari and his medicinal chemistry team at the University of Perugia (Italy), together with Professor Johan Auwerx and Dr. Kristina Schoonjans who lead a molecular biology and metabolic phenotyping group at the Ecole Polytechnique Federale de Lausanne (EPFL).

Highlights of the Cell Metabolism paper, titled "TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis", authored by Dr. Charles Thomas, et al., include:

  • INT-777, a derivative of the primary human bile acid cholic acid, is a potent and selective TGR5 agonist.
  • INT-777 induces the release of GLP-1 in the gut in a TGR5-dependent manner, an effect that is markedly enhanced when the compound is given in combination with a DPP4 inhibitor such as sitagliptin.
  • INT-777 normalizes glucose tolerance in obese, insulin resistant (DIO) and diabetic (db/db) mice; the treated mice maintain normal insulin levels and glucose uptake in liver and muscle.
  • INT-777 prevents weight gain and fat accumulation in mice on a high fat diet by increasing energy expenditure and fat burning; liver function is also protected with reduced steatosis, fibrosis and serum markers of liver damage in the treated mice.

Professor Pellicciari, a co-author on the paper, commented, "Years of concerted discovery efforts and proprietary know-how in bile acid chemistry have resulted in our ability to rationally design molecules that are highly selective for bile acid receptors. The realization of this in the novel TGR5 agonist INT-777 and the characterization of its mechanism of action represent an important milestone in the establishment of a novel class of therapeutic agents targeting this receptor."

Professor Johan Auwerx, who has led the field in uncovering the role of the TGR5 receptor and representing the lead authors at EPFL, added, "Our collaboration with the joint Intercept-Pellicciari team has been extremely fruitful. We are very pleased with the performance of INT-777, a compound that has allowed us to further elucidate this critical mechanism of TGR5 regulated GLP-1 release in the gut."

Dr. Mark Pruzanski, founder, President and CEO of Intercept and a co-author on the paper, commented further, "Diabetes, obesity and other associated metabolic disorders are reaching epidemic proportions. At Intercept we are uniquely positioned to exploit the therapeutic potential of modified bile acids, molecules that nature has designed to play a central role in the maintenance of metabolic homeostasis. In this context, TGR5 has emerged as an important target and INT-777 as an excellent candidate that we plan to advance into the clinic in 2010."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

Intercept's lead compound, INT-747, is a modified human bile acid and first-in-class FXR agonist that is currently in Phase II testing. Clinical proof of concept was recently demonstrated in a Phase II, placebo-controlled trial of INT-747 in type 2 diabetics with fatty liver disease. Based on these results, the company plans to advance INT-747 in a Phase IIb trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. INT-747 is completing two additional Phase II trials in patients with primary biliary cirrhosis, an autoimmune cholestatic liver disease and orphan indication. Results from the first of the two studies are expected in the fourth quarter of 2009.

INT-777 is a modified human bile acid and selective TGR5 agonist that is currently being assessed in IND-enabling studies.

For more information about Intercept, please go to www.interceptpharma.com; and for information about Intercept's lead investor, Genextra S.p.A., please go to www.genextra.it.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
2. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Consortium publishes Phase II map of human genetic variation
5. The Lancet Publishes Vasogens ACCLAIM Results
6. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
7. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Springer publishes anthology with the Nanoethics Group
9. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
10. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
11. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... PMG Research is pleased to announce its participation ... Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on how ... and bring them closer to the patient. Clinical Trial Collaborations also will present an ...
(Date:3/27/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is now offering a ... consumers who want to have their DarioHealth products reimbursed ... alliance agreements with partners across the U.S. who will ... approved, will supply and bill the customer,s insurance for ...
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
Breaking Biology Technology:
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... enables to match face pictures against each other or against large databases. The ... ... fastest software for biometric Face Matching on the market. The speed is at ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
Breaking Biology News(10 mins):